INTRODUCTION
============

Pulmonary hypertension is a rare and devastating disease characterized by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance which eventually leads to right ventricular failure and death ([@b4-jer-11-2-74]; [@b9-jer-11-2-74]). It may due to various etiologies such as left heart disease, parenchymal lung disease, chronic thromboembolic disease, hematologic disorders or it may be idiopathic in nature ([Table 1](#t1-jer-11-2-74){ref-type="table"}) ([@b25-jer-11-2-74]) though the clinical picture of these patients is similar. Patients with all forms of pulmonary hypertension present with progressive dyspnea and increasing exercise intolerance. More specifically WHO Group I pulmonary arterial hypertension (PAH) is due to direct injury to the pulmonary vessels and vascular bed. At present there is no cure for PAH, however over the past decade targeted pharmaceutical options have become available. In addition to these pharmaceutical options, exercise and pulmonary rehabilitation have also been shown to increase exercise capacity, WHO functional class, peak oxygen consumption and resting heart rate ([@b12-jer-11-2-74]; [@b13-jer-11-2-74]). It has also been seen that exercise may improve health related quality of life (HRQoL) ([@b7-jer-11-2-74]), depression ([@b29-jer-11-2-74]) and fatigue ([@b28-jer-11-2-74]). It is imperative that clinicians use pulmonary rehabilitation and exercise as an adjuvant therapy in the treatment of these patients as its benefits are clearly evident. This review will attempt to emphasize the importance of structured exercise training in the pulmonary hypertension population despite etiology and disease severity.

PULMONARY REHABILITATION
========================

Over the last few decades pulmonary rehabilitation has advanced as a therapeutic option in patients of chronic respiratory disease. Evidence based medicine has determined that pulmonary rehabilitation can reduce dyspnea, increase exercise tolerance and improve health related quality of life in all settings of chronic respiratory disease ([@b26-jer-11-2-74]). Pulmonary rehabilitation is defined as a comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies, which include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence of health-enhancing behaviors ([@b26-jer-11-2-74]).

Use of exercise training and pulmonary rehabilitation in cardiopulmonary diseases such as congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) have shown patient outcome improvement and are well described ([@b15-jer-11-2-74]; [@b23-jer-11-2-74]). However, in the setting of pulmonary hypertension only small cohorts of studies exist. The use of exercise training and pulmonary rehabilitation in a pulmonary hypertension population is still underutilized though studies have shown its beneficial effect ([@b8-jer-11-2-74]; [@b19-jer-11-2-74]).

PULMONARY ARTERIAL HYPERTENSION AND EXERCISE IMPAIRMENT
=======================================================

Pulmonary arterial hypertension is characterized by a progressive increase in pulmonary vascular resistance, leading to right ventricular failure and eventual death ([@b25-jer-11-2-74]). Prior to pharmacological intervention traditional therapies were utilized which included anticoagulants, diuretics, and supplemental oxygen. However, after the pathophysiologic process became well known disease-targeted therapies such as phosphodiesterase inhibitors, endothelin receptor antagonists and prostacyclins have become more widely used ([@b24-jer-11-2-74]). Combinations of these agents are used to decrease pulmonary vascular resistance, decrease pulmonary artery pressures and increase exercise tolerance ([@b22-jer-11-2-74]). Combination therapy with disease specific drugs has shown symptomatic relief as well as been shown to increase exercise capacity and possibly survival rate in pulmonary hypertension ([@b11-jer-11-2-74]; [@b16-jer-11-2-74]). Though these medications address quantitative measures of pulmonary vasculature and hemodynamics, exercise capacity and quality of life continue to decline despite optimized treatment.

Exercise capacity is reduced in the setting of pulmonary hypertension which is associated with depression and anxiety disorders as demonstrated by [@b18-jer-11-2-74]. Until a better understanding of exercise training in the setting of pulmonary hypertension was established the early thought process was that exercise and increased physical activity may be detrimental to these patients and may actually increase pulmonary pressures expediting the proliferative process ([@b3-jer-11-2-74]).

The pathogenesis of pulmonary hypertension is multifactorial. WHO group I pulmonary hypertension, also referred to as pulmonary arterial hypertension is characterized by abnormalities initiating in the small arteries of the pulmonary vasculature, including enhanced cell proliferation and reduced apoptosis, endothelial dysfunction, thrombosis *in situ*, inflammation, and plexiform arteriopathy, leading to vascular remodeling and excessive vasoconstriction ([@b20-jer-11-2-74]). This may due to connective tissue diseases, congenital heart disease, HIV infection, portal hypertension, heritable or it may be idiopathic in nature. In the setting of PAH these changes cause resistance for the blood flowing through the pulmonary arteries. This leads to increased pulmonary artery pressures and increased pulmonary vascular resistance pressures eventually leading to right heart failure due to increased after load, decreased contractility, and reduced cardiac output ([@b30-jer-11-2-74]). The combination of reduced cardiac output and increased pulmonary vascular resistance creates a situation where exertion causes dyspnea and negatively affects quality of life.

Exertional dyspnea being a common symptom across the pulmonary hypertension population provides a method to assess disease severity and progress. Dyspnea may be measures subjectively by using instruments such as the Borg Dyspnea Scale and Medical Research Council Dyspnea Scale ([@b5-jer-11-2-74]; [@b6-jer-11-2-74]). The severity of exertion is helpful to assess severity and prognosis in pulmonary hypertension. The 6-min walk test and the measure distance is used to assess exercise capacity in patients diagnosed with pulmonary disease and is used as the determinant and primary endpoint in many exercise training clinical trials ([@b2-jer-11-2-74]). Exercise tolerance can also be measured using cardiopulmonary exercise testing ([@b1-jer-11-2-74]).

CLINICAL TRIALS OF EXERCISE TRAINING AND PULMONARY REHABILITATION
=================================================================

Though early thought process advised against increased exertion and exercise a change in thinking brought upon clinical trials of exercise respiratory training in the pulmonary hypertension population ([Table 2](#t2-jer-11-2-74){ref-type="table"}). In [@b21-jer-11-2-74] conducted the first prospective randomized study to evaluate the effects of exercise on chronically ill pulmonary hypertension patients, stable on medication. Thirty patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension were randomly assigned to either a control or training group. Primary end points were the change in 6-min walk distance from baseline to week 15 in the scores of the Short Form Health Survey quality-of-life questionnaire (SF-36). Secondary endpoints were also assessed. At week 15, patients in the primary and secondary training groups had an improved 6-min walking distance. Exercise training was shown to be well tolerated and improved scores of quality of life, WHO functional class and peak oxygen consumption. Systolic pulmonary artery pressure values at rest did not change significantly after 15 weeks of exercise and respiratory training ([@b21-jer-11-2-74]).

Though the ground work for exercise training in pulmonary hypertension was laid out, furthering testing was required. [@b8-jer-11-2-74] conducted a trial of exercise on only patients with WHO Group I PAH. Nineteen clinically stable PAH patients with moderate disease underwent exercise training program for 12 weeks in which maximal capacity endurance capacity and quadriceps function were assessed and serial quadriceps muscle biopsies were obtained. 6-min walk distance and peak exercise capacity did not change after training. However, endurance capacity improved significantly after training. Training also enhanced aerobic capacity of the quadriceps, by increasing capillarization ([@b8-jer-11-2-74]).

A study by [@b10-jer-11-2-74] of 22 PAH or CTEPH patients demonstrated significant increase in 6 MWD as well as Peak VO~2~. The rehabilitation program consisted of 24 1-h sessions of exercise training/rehabilitation over the course of 12 weeks. Peak work rate during cardiopulmonary exercise test also increased in the rehabilitation group with borderline significance. Echocardiography and blood N-terminal pro-brain natriuretic peptide levels were unchanged. No adverse events occurred due to the rehabilitation program demonstrating safety.

With evidence of the positive benefits of exercise training in the setting of pulmonary hypertension further clinical trials were conducted. [@b12-jer-11-2-74] demonstrated the benefits of exercise training in a connective tissue disease population with pulmonary hypertension ([@b14-jer-11-2-74]). Patients with RHC confirmed connective tissue disease related pulmonary hypertension received in-hospital exercise training for 3 weeks which was continued for another 12 weeks at home. Patients improved the mean distance walked in 6 min, resting heart rate, peak oxygen consumption, and oxygen saturation. In addition systolic pulmonary artery pressure, and diastolic systemic blood pressure improved significantly after 3 weeks of exercise training. The 1- and 2-yr overall-survival rates were found to be 100%, the 3-yr survival rate 73% ([@b13-jer-11-2-74]).

Another study by [@b12-jer-11-2-74] aimed to assess disease progression and survival in patients with severe chronic pulmonary hypertension. Fifty eight patients with severe pulmonary hypertension on stable medication received exercise and respiratory training in hospital for 3 weeks which was later continued at home. They were prospectively followed for 24±12 months. Primary endpoints were time to clinical worsening and survival. Adverse events and changes in the 6-min walking test, QoL, WHO functional class and gas exchange were secondary endpoints and were evaluated at baseline and at weeks 3 and 15. The results showed that all patients tolerated the exercise training well without any severe adverse events. In week 15, 6-min walking test results were significantly improved compared to baseline as well as quality of life scores, WHO functional class, peak oxygen consumption, heart rate at rest and maximal workload. Survival at 1 and 2 yr was 100 and 95%, respectively ([@b12-jer-11-2-74]). Fifteen events occurred during the follow-up. It was concluded that exercise and respiratory training as add-on to medical treatment may improve exercise capacity and QoL, with a good long term safety profile.

NON PHYSICAL EFFECTS OF EXERCISE AND PULMONARY REHABILITATION
=============================================================

As pulmonary hypertension's most debilitating manifestation is exercise intolerance most trials focus on improvement in this characteristic as well as hemodynamics. However, in addition to physical improvement, there is a great deal of improvement in aspects of psychosomatic domains. It is well known that patients with pulmonary hypertension experience depression ([@b29-jer-11-2-74]) and report increased levels of fatigue severity ([@b28-jer-11-2-74]). It is also well known that these patients have a severely impaired health related quality of life ([@b27-jer-11-2-74]). These aspects of psychosomatic medicine may also be addressed with the use of structured pulmonary rehabilitation and exercise programs in this population. A study by [@b17-jer-11-2-74] showed the effects that dyspnea has on depression and health related quality of life (HRQoL). Pulmonary rehabilitation programs have also showed improvement in fatigue severity as well as depression ([@b28-jer-11-2-74]) which provide evidence of further benefits of such programs.

A more recent study by [@b7-jer-11-2-74] went ahead to determine the effects of intense treadmill exercise on cardio-respiratory function as well as quality of life in patients with pulmonary hypertension. Patients were randomized to a 10-week disease specific education only group or education/exercise combined group. The exercise program consisted of 24--30 sessions of treadmill walking for 30--45 min per session. Outcome variables included changes in 6-min walk test (6 MWT) distance, time to exercise intolerance, peak work rate from a cardiopulmonary treadmill test, and quality-of-life measures, including the SF-36 and Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) ([@b7-jer-11-2-74]). The results following 10 weeks of intervention, demonstrated an improvement in 6 MWT distance, increased time to exercise intolerance, and peak WR. Additionally, the exercise group showed increased quality of life score according to the SF-36 as well as the CAMPHOR scale ([@b7-jer-11-2-74]).

CONCLUSIONS
===========

Pharmacotherapy for pulmonary arterial hypertension has advanced over the past decade and has provided clinicians with a disease specific approach which has led to the improvement in prognosis of PAH patients. However, patients continue to experience significant exertional symptoms accompanied by reduced functional capacity and diminished health-related quality of life. From the trials that have been conducted, the evidence supports the benefits and safety of exercise training and rehabilitation programs in the pulmonary hypertension populations. Initial exercise training and pulmonary rehabilitation programs were assessed in a stable, treated, systolic heart failure, and COPD and showed improved functional capacity and reduced exercise intolerance, symptoms of dyspnea, and fatigue.

Trials conducted in a pulmonary hypertension population showed improvement in exercise endurance and muscle strength as well as quality of life with the implementation of exercise training and cardiopulmonary rehabilitation as part of their medical care without a good safety profile. In conjunction with pharmacotherapy all patients with confirmed pulmonary arterial hypertension should be treated with a pulmonary rehabilitation and exercise training program.
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###### 

World Health Organization's classification of pulmonary hypertension ([@b25-jer-11-2-74])

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  **Group I - Pulmonary Arterial hypertension (PAH)**
    Idiopathic PAH
    Heritable PAH (BMPR2, ALK1, ENG, SMAD9, CAV1, KCNK3, Unknown)
    Drug and toxin induced
    Associated with (i) Connective tissue disease, (ii) HIV infection, (iii) Portal hypertension, (iv) Congenital heart disease, (v) Schistosomiasis
    Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
    Persistent pulmonary hypertension of the newborn
  **Group II - Pulmonary hypertension due to left heart disease**
    Left ventricular systolic dysfunction
    Left ventricular diastolic dysfunction
    Valvular disease
    Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
  **Group III - Pulmonary hypertension due to lung diseases and/or hypoxia**
    Chronic obstructive pulmonary disease
    Interstitial lung disease
    Other pulmonary diseases with mixed restrictive and obstructive pattern
    Sleep-disordered breathing
    Alveolar hypoventilation disorders
    Chronic exposure to high altitudes
    Developmental lung disease
  **Group IV - Chronic thromboembolic pulmonary hypertension (CTEPH)**
  **Group V - Pulmonary hypertension with unclear multifactorial mechanisms**
    Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
    Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleimyomatosis
    Metabolic disorders: glycogen storage disease, Gaucher's disease, hypothyroidism
    Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary hypertension
  ----------------------------------------------------------------------------------------------------------------------------------------------------

5th World Symposium on Pulmonary Hypertension, Nice, France 2013. BMPR, Bone Morphogenic Protein Receptor Type II; CAV1, Caveolin-1; ENG, Endoglin; HIV, Human Immunodeficiency Virus.

###### 

Summary of exercise testing trial in the setting of pulmonary hypertension

  Study                n     Study Design                  Intervention                                                                                                     Duration of Exercise/Rehab Program                   Results
  -------------------- ----- ----------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  [@b21-jer-11-2-74]   30    RCT                           Bicycle training, Walking, Dumbbell, Respiratory Training                                                        3 week in hospital+12 weeks at home                  Improvement in 6MWD, QOL scores, WHO FC, VO~2~ (peak +AT) and workload. No change in SPAP; No SAE
  [@b8-jer-11-2-74]    19    Non-randomized single group   Bicycle Training, Quadriceps stretch and endurance                                                               12 weeks in rehabilitation center                    Stable 6MWD, peak exercise capacity. Increased muscle strength, capillaries in muscle, oxidative enzyme activity.
  [@b7-jer-11-2-74]    23    RCT                           Treadmill walking only for 30--45 min.                                                                           10 weeks 24--30 session in rehabilitation facility   Increase in 6MWD, QOL scores, Time to exercise intolerance, Peak work rate; No SAE
  Fox et al., 2010     22    NRCT                          1 hr. per session, aerobic interval training, bicycle, treadmill, walking, step climbing; resistance training.   12 weeks in outpatient rehabilitation center         Increase in 6MWD, Peak VO~2~, Peak WR. BNP, SPAP and CO remained the same; No SAE
  [@b12-jer-11-2-74]   58    NRCT single group             Daily bicycle training, dumbbell training, respiratory training                                                  3 weeks in hospital, 12 week at home                 Increased 6MWD, QOL scores, WHO FC, Peak VO~2~, Maximum workload and decreased resting HR; No SAE
  [@b13-jer-11-2-74]   183   NRCT single group             Daily interval bicycle training, walking, dumbbell training, mental training, home                               3 weeks in hospital, 12 week at home                 Increased 6MWD, QOL scores, WHO FC, Peak VO~2~; Decreased resting heart rate, and SPAP; No SAE
  [@b13-jer-11-2-74]   21    NRCT single group             Daily interval bicycle training, walking, dumbbell training, mental training, home training                      3 weeks in hospital, 12 week at home                 Increased 6MWD, QOL scores, WHO FC, Peak VO~2~, Maximum workload increased O~2~ SPAP; Survival at 2 yr-100%, 3 yr 73%

RCT, Randomized Controlled Trial; 6MWD, 6-min walk distance; QOL, Quality of life; WHO-FC, World Health Organization Functional Class; SAE, Serious Adverse Events; NRCT, Non-Randomized Control Trial; HR, Heart Rate; BNP, Brain Natruietric Peptide; SPAP, Systolic Pulmonary Artery Pressure.
